Then we will discuss the investigations of preclinical NPs that are either loaded with single or multiple therapies to optimize the tumor microenvironment for combination with separately administered PD-1/PD-L1 blocking therapy, or NPs co-loaded with the immune checkpoint blocking agents and other therapies (Figure 1). Here, CD274 is linked to neoplasm.